Quarterly report · Q2
8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥679.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥620.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥695.9bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥495.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.7bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥102.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.39 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.84 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.62 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥654.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥631.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥708.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥679.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥996m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.5bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥45.4bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥819m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥312m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥597.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥572.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥667m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥649.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥620.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 580
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 688000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 641000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -1304000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -502000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 234000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 679000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -545000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -431000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -701000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -189000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1YTDDuration | 857000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | CurrentYTDDuration | 52000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1YTDDuration | － | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | CurrentYTDDuration | -254000000 | JPY |
| Proceeds from sales of stocks of subsidiaries and affiliates inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of stocks of subsidiaries and affiliates inv cf | CurrentYTDDuration | 10000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1YTDDuration | － | JPY |
| Payments for transfer of business2 inv cf | CurrentYTDDuration | -105000000 | JPY |
| Payments for asset retirement obligations inv cf | Prior1YTDDuration | -56000000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYTDDuration | -4000000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -161000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 160000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 205000000 | JPY |
| Other net inv cf | Prior1YTDDuration | 55000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 159000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -1445000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -407000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 509000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -242000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 3610000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -1333000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -5044000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -320000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -226000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -1057000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -1058000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -2202000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -2960000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 7945000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 7324000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 88882000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 90014000000 | JPY |
| Increase in cash and cash equivalents resulting from merger cce | Prior1YTDDuration | － | JPY |
| Increase in cash and cash equivalents resulting from merger cce | CurrentYTDDuration | 83000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | Prior1YTDDuration | 296000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | CurrentYTDDuration | 432000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |